3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.
OBJECTIVE
Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment.


METHODS
Patients on PD were dialyzed with a conventional PD fluid containing 43 micromol/L 3,4-DGE and 281 micromol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 micromol/L 3,4-DGE and 200 micromol/L 3-DG.


RESULTS
The 3,4-DGE concentration in the peritoneum declined at a much higher rate during the dwell than did the 3-DG concentration. However, 3,4-DGE was not detected in the plasma of patients or of rats during dialysis. The 3-DG concentration in plasma peaked shortly after infusion of fluid into the peritoneal cavity. The 3,4-DGE concentration during experimental incubation in plasma declined rapidly; the 3-DG concentration declined only 10% as rapidly (or less).


CONCLUSIONS
During dialysis, 3,4-DGE could not be detected in plasma of either PD patients or rats, presumably because of its high reactivity. On the other hand, 3-DG may pass through the membrane and be detected in the blood.
Erixon
Martin
M
Gambro AB, University of Lund, Lund, Sweden. martin.erixon@gambro.com
Wieslander
Anders
A
Lindén
Torbjörn
T
Carlsson
Ola
O
Jönsson
Jan Ake
JA
Simonsen
Ole
O
Kjellstrand
Per
P
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D017127:Glycation End Products, Advanced / Q000378:metabolism; D024981:Glycogen Phosphorylase / Q000037:antagonists & inhibitors; D006801:Humans; D007274:Injections, Intraperitoneal; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D010530:Peritoneal Dialysis / Q000379:methods*; D010537:Peritoneum / Q000187:drug effects / Q000378:metabolism; D011753:Pyrones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
C504711:3,4-dideoxyglucosone-3-ene; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D011753:Pyrones; D024981:Glycogen Phosphorylase